Loading
Lung cancer leader behind trials that changed treatment of EGFR-mutant and stage III disease.
John Heymach is Chair of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center. A medical oncologist and cancer biologist specialising in lung cancer, targeted therapy and immunotherapy, he was principal investigator of AEGEAN, the perioperative durvalumab trial, and leads EGFR and KRAS-directed programmes including work on osimertinib in stage III disease in the LAURA trial and on targeting drug-tolerant persister cells. His papers report perioperative durvalumab for resectable non-small-cell lung cancer in the New England Journal of Medicine and the ZODIAC phase 3 trial of vandetanib plus docetaxel as second-line treatment in advanced non-small-cell lung cancer. His work also covers small-cell lung cancer and head and neck squamous cell carcinoma.
| Title | Journal | Year |
|---|---|---|
| Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer | New England Journal of Medicine | 2023 |
| Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial | Lancet Oncology | 2010 |
Perioperative immunotherapy is now standard for resectable lung cancer without a targetable driver. The updated overall survival hazard ratio of 0.89, with a confidence interval crossing one, is the honest state of the evidence on whether it cures more people.
It offers the first credible explanation for why only a minority of small-cell patients get a durable benefit from checkpoint blockade, and it introduces subtype switching, which would mean retesting at relapse rather than typing once.
Shares HER2-mutant non-small-cell lung cancer, Resectable stage I to III non-small-cell lung cancer, Durvalumab, Small-cell lung cancer.
Shares Osimertinib, Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Durvalumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Osimertinib, Resectable stage I to III non-small-cell lung cancer, Durvalumab, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Durvalumab, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Osimertinib, Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Osimertinib, Head and neck squamous cell carcinoma, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Beamion LUNG-1, HER2-mutant non-small-cell lung cancer.